Search filters

List of works by Carmen Fava

A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.

scientific article

Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.

scientific article published in June 2008

Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.

scientific article

BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.

scientific article published on January 2015

BCR-ABL1 mutation ≠ ponatinib resistance

scientific article published in February 2016

Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?

scientific article published on October 2010

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

scientific article

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

scientific article published on 18 June 2020

Concomitant occurrence of BCR-ABL and JAK2V617F mutation

scientific article published on 01 September 2011

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

scientific article published on 25 June 2011

Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor

scientific article published on April 2016

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

scientific article

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

scientific article published on September 2016

HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)

scientific article published on 14 October 2011

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

scientific article published on 27 August 2016

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

scientific article published in August 2013

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

scientific article published on 10 October 2012

Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia.

scientific article published on October 2009

Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia

scientific article published on 03 January 2014

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

scientific article published on 25 June 2015

Milestones and monitoring

scientific article published on June 2015

Molecular Resistance: An Early Indicator for Treatment Change? ⬇️

scientific article published on January 28, 2012

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

scientific article (publication date: 21 March 2011)

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

scientific article published on 12 October 2009

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

scientific article published on 16 July 2012

Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia.

scientific article published on June 2014

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

scientific article published on 2 October 2017

Ponatinib for chronic myeloid leukaemia: future perspectives

scientific article published on 12 April 2016

Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells

scientific article published on 04 July 2019

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

scientific article published on 30 May 2018

Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.

scientific article

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

scientific article published on 2 May 2017

The choice of first-line chronic myelogenous leukemia treatment

scientific article

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.

scientific article

The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia

scientific article published on 7 November 2015

Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia

scientific article

Update on emerging treatments for chronic myeloid leukemia.

scientific article published on 31 March 2015

Paulina is supported by:

About Paulina

Help